Safety and Effectiveness of Belotero® in Subjects With Fitzpatrick Phototypes IV Through VI
This study has been completed.
Information provided by (Responsible Party):
Merz Pharmaceuticals, LLC
First received: June 3, 2009
Last updated: April 19, 2013
Last verified: April 2013
This is a study to assess how safe and effective an investigational product, Belotero® is in people with all skin types with facial wrinkles, such as nasolabial folds. Nasolabial folds are wrinkles on the face that go from outside of the nostrils to the edges of the mouth.
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Multicenter Study of The Safety and Effectiveness of Dermal Filler, Belotero®, After Mid-to-Deep Dermal Implantation for Correction of Moderate to Severe Facial Wrinkles (Such as Nasolabial Folds) Over 24 Weeks in Subjects With Fitzpatrick Phototype Scores of IV, V, and VI.
Primary Outcome Measures:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||July 2010 (Final data collection date for primary outcome measure)
Hyaluronic acid dermal filler, Belotero®, single use syringe, injected into mid to deep dermal layer
- Nasolabial folds
The Fitzpatrick Skin Phototype Scale goes from number 1 (I), which is the very lightest skin tone, to number 6 (VI) which is the very darkest skin tone. This study is to determine the safety and effectiveness of Belotero® in people with skin phototypes of 1(I)thru 6 (VI).
|Ages Eligible for Study:
||18 Years to 75 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Had reviewed and signed a statement of Informed Consent and HIPAA authorization. In addition, subjects were asked to provide a separate release for use of their photographs in publications. Subjects had a right to refuse the photo release without jeopardizing their eligibility to participate in the study.
- Was 18 to 75 years of age, of any race or sex.
- If female, was post-menopausal for at least one year; or had undergone a hysterectomy; or a tubal ligation; or if of childbearing potential, had negative urine pregnancy test results and agreed to use an approved method of birth control throughout the study (ie, oral/systemic contraceptives, intrauterine device [IUD], or spermicide in combination with a barrier method of contraception), or was abstinent, or was in a monogamous relationship with a partner who had had a vasectomy.
- Had bilateral nasolabial folds with a severity of 2 or 3 on the wrinkle severity rating scale (SRS) as assessed by the Evaluator Investigator.
- Subjects were to have been rated IV, V, or VI on the Fitzpatrick Skin Phototype Scale.
- Had adequate understanding of the language (spoken and written English or Spanish) and was willing to comply with the study requirements.
- A personal history of allergic/anaphylactic reactions including hypersensitivity to local anesthetics (eg, lidocaine, etc), hyaluronic acid (HA) preparations, and/or gram-positive bacterial protein.
- A known history of keloids or bleeding disorders.
- Leukoderma (vitiligo) or a family history of leukoderma or other pigmentary disorders.
- An active inflammatory process in the nasolabial fold area (skin eruptions such as cysts, pimples, rashes, cancerous/pre-cancerous lesions, psoriasis, neurodermatitis, or any other active skin disease) or severe scarring that might interfere with study assessments.
- If female, pregnant, planning to become pregnant during the study, or breast feeding.
- Planned to undergo major facial surgery during the course of the study (eg, rhinoplasty [with or without implant], facelift, congenital defect repair, etc).
- Clinically important disease, as judged by the investigator, within 3 months of the study (eg, significant laboratory test abnormalities, myocardial infarct, stroke, cancer, connective tissue diseases [scleroderma, systemic lupus erythematous], systemic infection, uncontrolled diabetes, etc.), including those with medical conditions that might require the use of immunosuppressive medications during the trial (eg, severe, uncontrolled asthma, rheumatoid arthritis, autoimmune diseases, etc).
- Severe physical, neurological or mental disease.
- Excessive facial hair that might interfere with the evaluation of the wrinkle assessments.
- Any systemic or dermatologic disorder, which, in the opinion of the investigator, would interfere with the study results or increase the risk of AEs.
- Had used exclusionary medications/treatments.
- Participation in a clinical investigation within the 30 days prior to the first planned device administration or during this trial.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00922623
|Pearl E Grimes
|Los Angeles, California, United States, 90036 |
|Mitchellville, Maryland, United States, 20721 |
|Jeanine B Downie
|Montclair, New Jersey, United States, 07042 |
Merz Pharmaceuticals, LLC
||Rhoda Narins, MD
||Dermatology Surgery and Laser Center
No publications provided
||Merz Pharmaceuticals, LLC
History of Changes
|Other Study ID Numbers:
||MUS 90028-0622/1 Supplement
|Study First Received:
||June 3, 2009
|Results First Received:
||December 22, 2011
||April 19, 2013
||United States: Food and Drug Administration
Keywords provided by Merz Pharmaceuticals, LLC:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 16, 2013